drugset / Trial / NCT01577732
Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers
NaSingle-groupOpen-labelPrevention
Summary
This study aims to evaluate the safety and reactogenicity of a booster dose of Infanrix-IPV+Hib™ when administered to healthy Vietnamese toddlers at 12 to 24 months of age who were vaccinated previously against diphtheria, tetanus, and pertussis diseases within their first six months of lives.
Timeline
- Start
- 2012-12-08
- Primary completion
- 2013-04-09
- Completion
- 2013-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infanrix-IPV+Hib™ | Vaccine | — | Intramuscular |